|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 65.20 EUR | -1.14% |
|
+3.00% | +2.44% |
Published on 07/09/2025 at 06:05 am EDT
Contact us to request a correction
Finnish pharmaceutical company Orion has raised its forecasts for 2025.
Sales are now expected to reach between €1,630 million and €1,730 million, up from the previous estimate of €1,550 million to €1,650 million.
Operating profit is projected to be in the range of €400 million to €500 million, compared to the earlier forecast of €350 million to €450 million.
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Select your edition
All financial news and data tailored to specific country editions
